Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AD-2281 + AD-2282 | Experimental |
| |
| AD-2281 + Placebo of AD-2282 | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-2281 | Drug | PO, Once daily, 8weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change rate of LDL-C | Percent change (%) of LDL-C from baseline at week 8 | from baseline at 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| JeongEun Park | Contact | +82-31-891-6989 | parkje@addpharma.co.kr |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AD-2282 |
| Drug |
PO, Once daily, 8weeks |
|
| Placebo of AD-2282 | Drug | PO, Once daily, 8weeks |
|